These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 33984052)

  • 1. Correction: Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    PLOS ONE Staff
    PLoS One; 2021; 16(5):e0251897. PubMed ID: 33984052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
    Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
    PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches.
    Ali HA; Lomholt AF; Mahmoudpour SH; Hermanrud T; Bygum A; von Buchwald C; Jakobsen MA; Rasmussen ER
    PLoS One; 2019; 14(12):e0227056. PubMed ID: 31856251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.
    Bae DJ; Tehrani DM; Rabadia SV; Frost M; Parikh RV; Calfon-Press M; Aksoy O; Umar S; Ardehali R; Rabbani A; Bokhoor P; Nsair A; Currier J; Tobis J; Fonarow GC; Dave R; Rafique AM
    Am J Cardiol; 2020 Oct; 132():150-157. PubMed ID: 32819683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
    Salvador GL; Marmentini VM; Cosmo WR; Junior EL
    Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.
    Coleman CI; Weeda ER; Kharat A; Bookhart B; Baker WL
    Diabet Med; 2020 Jan; 37(1):44-52. PubMed ID: 31407377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Ku E; McCulloch CE; Vittinghoff E; Lin F; Johansen KL
    J Am Heart Assoc; 2018 Oct; 7(19):e009992. PubMed ID: 30371331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation.
    Ido A; Hasebe N; Takeuchi T; Kikuchi K
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S133-7. PubMed ID: 12688410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
    Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
    Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.
    Roshanov PS; Rochwerg B; Patel A; Salehian O; Duceppe E; Belley-Côté EP; Guyatt GH; Sessler DI; Le Manach Y; Borges FK; Tandon V; Worster A; Thompson A; Koshy M; Devereaux B; Spencer FA; Sanders RD; Sloan EN; Morley EE; Paul J; Raymer KE; Punthakee Z; Devereaux PJ
    Anesthesiology; 2017 Jan; 126(1):16-27. PubMed ID: 27775997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
    Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
    Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
    Hamada M; Hara Y; Ohtsuka T; Suzuki J; Saeki H; Ogimoto A; Shigematsu Y
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S5-10. PubMed ID: 12688389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
    Edmonston DL; South AM; Sparks MA; Cohen JB
    Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic study of ACE, AGT, CYP11B1, CYP11B2 and eNOS gene variants in hypertensive patients from Faisalabad, Pakistan.
    Hussain M; Bilal A; Awan FR
    J Pak Med Assoc; 2020 Apr; 70(4):624-629. PubMed ID: 32296206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
    Sommerstein R; Kochen MM; Messerli FH; Gräni C
    J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
    [No Abstract]   [Full Text] [Related]  

  • 16. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
    Simko F; Baka T
    Clin Sci (Lond); 2021 Apr; 135(8):1009-1014. PubMed ID: 33881142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.
    Shunan F; Jiqing Y; Xue D
    J Renin Angiotensin Aldosterone Syst; 2018; 19(4):1470320318803495. PubMed ID: 30296880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
    Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
    J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.